AMINOPYRAZOLOPYRIMIDINE COMPOUND USED AS INHIBITOR OF TYROSINE KINASE RECEPTOR OF NEUROTROPHIC FACTOR Russian patent published in 2022 - IPC C07D487/04 A61K31/519 A61K31/5377 A61P35/00 

FIELD: organic chemistry; pharmacology.

SUBSTANCE: group of inventions relates to the field of organic chemistry and pharmacology, namely to a compound that can inhibit the activity of Trk kinase. The compound is represented by the formula I or its pharmaceutically acceptable salt, where R¹, R⁴ and R⁷ are hydrogen; R² is selected from a group consisting of hydrogen, C_1-6alkyl, -C(=O)R⁹, -C(=O)NHR⁹ and -S(=O)₂R⁹, where C_1-6alkyl is not substituted or substituted with one substituent independently selected from a group consisting of 6-element aliphatic heterocyclyl and optionally substituted phenyl; R³ is selected from a group consisting of hydrogen, halogen, cyano, -C(=O)R¹⁰, -C(=O)NR¹⁰R¹¹, -C(=S)NR¹⁰R¹¹, phenyl and 5-element aromatic heterocyclyl, where phenyl and 5-element aromatic heterocyclyl, each independently, are not substituted or substituted with one substituent independently selected from a group consisting of C_1-6alkyl, C_1-6alkoxycarbonyl, morpholinyl and optionally substituted pyrrolidinyl carbonyl; R⁵ and R⁶ are independently selected from a group consisting of hydrogen, halogen and hydroxy, or R⁵ and R⁶ together form oxo; R⁸ is phenyl that is not substituted or substituted with one or two substituents independently selected from halogen; R⁹ is selected from a group consisting of C_1-6alkyl and phenyl, where phenyl is not substituted or substituted with one substituent independently selected from C_1-6alkyl; R¹⁰ and R¹¹ are independently selected from a group consisting of hydrogen, hydroxy, C_1-6alkyl, C_1-6alkoxy, 3-6-element cycloalkyl and phenyl, where C_1-6alkyl, C_1-6alkoxy, 3-6-element cycloalkyl and phenyl, each independently, are not substituted or substituted with one, two or three substituents independently selected from a group consisting of halogen, hydroxy, C_1-4alkyl and hydroxy(C_{1- 6}alkyl) group, 2,2-dimethyl-1,3-dioxolan-4-yl and N,N-di(C_1-4alkyl)amino; or R¹⁰ and R¹¹, together with N, to which they are attached, form 5-element aliphatic heterocycle that is not substituted or substituted with one substituent selected from hydroxy, where “optionally substituted” means that the group can be not substituted or substituted with one substituent independently selected from hydroxy or C_1-6alkoxy, and the specified “aliphatic heterocycle” or “aromatic heterocycle” contain 1-2 heteroatoms independently selected from sulfur, oxygen and/or nitrogen. The group of inventions also relates to specific compounds, a pharmaceutical composition based on it, their use in the preparation of a drug and a method for the treatment of a disease mediated by Trk.

EFFECT: providing the effective treatment or prevention of a disease mediated by the tyrosine kinase receptor Trk.

39 cl, 4 tbl, 52 ex